Abstract
Rationale
S100B is an astrocytic, calcium-binding protein which in nanomolar concentrations has neuroprotective and regenerating effects on neurons and glial cells. Increased levels have been shown to be positively correlated with therapeutic response in major depression. Event-related potentials (ERP) have been reported to be impaired in depressed patients.
Objectives
The aim of our study was to assess the relationship between S100B and visually evoked ERP in depression.
Methods
ERP and S100B serum concentration were studied in 18 patients with major depression, before and after 4 weeks of antidepressant treatment.
Results
The S100B concentration in patients was increased at intake and after 4 weeks of treatment compared to healthy controls. Initially increased P3-latency normalized and P2-latency significantly decreased after 4 weeks of treatment, although only in patients with clearly elevated initial S100B levels (mean plus 2 SD of the healthy controls).
Conclusion
The neuroregenerative activity of moderately increased S100B levels in major depression might be a factor contributing to a decrease of prolonged ERP parameters in major depression during antidepressant treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arolt V, Peters M, Erfurth A, Wiesmann M, Missler U, Kirchner H, Rothermundt M (2003) S100B and response to treatment in major depression: a pilot study. Eur Neuropsychopharmacol 13:235–239
Bange F, Bathien N (1998) Visual cognitive dysfunction in depression: an event-related potential study. Electroencephalogr Clim Neurophysiol 108:472–481
Blackwood DH, Whalley LJ, Christie JE, Blackburn IM, St Clair DM, McInnes A (1987) Changes in auditory P3 event-related potential in schizophrenia and depression. Br J Psychiatry 150:154–160
Bruder GE, Towey JP, Stewart JW, Friedman D, Tenke C, Quitkin FM (1991) Event-related potentials in depression: influence of task, stimulus hemifield and clinical features on P3 latency. Biol Psychiatry 30:233–246
Dierks T, Frolich L, Ihl R, Maurer K (1994) Event-related potentials and psychopharmacology. Cholinergic modulation of p 300. Pharmacopsychiatry 27:72–74
Dietrich DE, Hauser U, Peters M, Zhang Y, Wiesmann M, Hasselmann M, Rudolf S, Jüngling O, Kirchner H, Münte T, Arolt V, Emrich HM, Sönke J, Rothermundt M (2004) Target evaluation processing correlates with serum levels of nerve tissue protein S100B in patients with remitted major depression. Neurosci Lett 354:69–73
Donato R (2001) S100: a multigenetic family of calcium-modulated proteins of EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33:637–668
Evers S, Quibeldey F, Grotemeyer KH, Suhr B, Husstedt IW (1999) Dynamic changes of cognitive habituation and serotonin metabolism during the migraine interval. Cephalalgia 19:485–491
Evers S, Böckermann I, Nyhuis PW (2001) The impact of transcranial magnetic stimulation on cognitive processing: an event-related potential study. Neuroreport 12:2915–2918
Gangadhar BN, Ancy J, Janakiramaiah N, Umapathy C (1993) P300 amplitude in non-bipolar, melancholic depression. J Affect Disord 28:57–60
Grabe HJ, Ahrens N, Rose HJ, Keller C, Freyberger HJ (2001) Neurotrophic factor S100beta in major depression. Neuropsychobiology 44:88–90
Halgren E, Squires NK, Wilson CL, Rohrbaugh JW, Babb TL, Crandall PH (1980) Endogenous potentials generated in the Human hippocampal formation and amygdala by infrequent events. Science 210:803–805
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296
Hegerl U, Gallinat J, Juckel G (2001) Event-related potentials: do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists? J Affect Disord 62:93–100
Hetzel G, Moeller O, Erfurth A, Michael N, Rothermundt M, Arolt V, Evers S (2004) The impact of the selective monoamine reuptake inhibitors reboxetine and citalopram on visually-evoked event-related potentials in depressed patients. Pharmacopsychiatry (in press)
Himani A, Tandon OP, Bhatia MS (1999) A study of P300-event related evoked potential in the patients of major depression. Ind J Physiol Pharmacol 43:367–372
Lara DR, Gama CS, Belmonte-de-Abreu P, Portela LV, Goncalves CA, Fonseca M, Hauck S, Souza DO (2001) Increased serum S100B protein in schizophrenia: a study in medication-free patients. J Psychiatr Res 35:11–14
Machado-Vieira R, Lara DR, Portela LV, Goncalves CA, Soares JC, Kapczinski F, Souza DO (2002) Elevated serum S100B protein in drug-free bipolar patients during first manic episode: a pilot study. Eur Neuropsychopharmacol 12:269–272
Manji HK, Drevets WC, Charney DS (2001) The cellular neurobiology of depression. Nat Med 7:541–547
Mulert C, Juckel G, Augustin H, Hegerl U (2002) Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective reuptake inhibitor citalopram in major depression. Clin Neurophysiol 113:1566–1572
Nelson CA, Collins PF, Torres F (1991) P300 brain activity in seizure patients preceding temporal lobectomy. Arch Neurol 48:141–147
Okada YC, Kaufman L, Williamson SJ (1983) The hippocampal formation as a source of the slow endogenous potentials. Electroencephalogr Clin Neurophysiol 55:417–426
Paige SR, Hendricks SE, Fitzpatrick DF, Balogh S, Burke WJ (1995) Amplitude/intensity functions of auditory event-related potentials predict resposiveness to bupropion in major depression disorder. Psychopharmacol Bull 31:243–248
Pascual-Leone A, Rubio B, Pallardo F, Catala MD (1996) Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet 348:233–237
Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H (2001a) Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 6:445–449
Rothermundt M, Arolt V, Wiesmann M, Missler U, Peters M, Rudolf S, Kirchner H (2001b) S100B is increased in melancholic but not in non-melancholic major depression. J Affect Disord 66:89–93
Rothermundt M, Peters M, Prehn JH, Arolt V (2003) S100B in brain damage and neurodegeneration. Microsc Res Tech 60:614–632
Rothermundt M, Ponath G, Glaser T, Hetzel G, Arolt V (2004) S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia. Neuropsychopharmacology (in press). Advance online publication DOI 10.1038/sj.npp.1300403
Schroeter ML, Abdul-Khaliq H, Diefenbacher A, Blasig IE (2002) S100B is increased in mood disorder and may be reduced by antidepressive treatment. Neuroreport 13:1675–1678
Simson R, Vaughn HG, Ritter W (1977) The scalp topography of potentials in auditory and visual discrimination tasks. Electroencephalogr Clin Neurophysiol 42:528–535
Vandoolaeghe E, van Hunsel F, Nuyten D, Maes M (1998) Auditory event related potentials in major depression: prolonged P300 latency and increased P200 amplitude. J Affect Disord 48:105–113
Wittchen H-O, Pfister H (1997) Diagnostisches expertensystem für psychische Störungen DIA-X. SWETS Test Services, Frankfurt
Yanai I, Fujikawa T, Osada M, Yamawaki S, Touhouda Y (1997) Changes in auditory P300 in patients with major depression and silent cerebral infarction. J Affect Disord 46:263–271
Yingling CD, Hosobuchi Y (1984) A subcortical correlate of P300 in man. Electroencephalogr Clin Neurophysiol 59:72–76
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hetzel, G., Moeller, O., Evers, S. et al. The astroglial protein S100B and visually evoked event-related potentials before and after antidepressant treatment. Psychopharmacology 178, 161–166 (2005). https://doi.org/10.1007/s00213-004-1999-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-004-1999-z